Clinical trial
A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1
NCT01185860 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2009
- Completion date
- January 31, 2012
- Enrollment
- 59 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.